Key terms
About MTEM
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2001 and is headquartered in Austin, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MTEM news
Apr 12
4:32pm ET
Molecular Templates Inc Announces Layoffs, CMO Resignation
Apr 11
11:20am ET
Biotech Alert: Searches spiking for these stocks today
Mar 29
8:30am ET
Bristol Myers ends collaboration agreement with Molecular Templates
Mar 29
8:28am ET
Molecular Templates reports Q4 EPS (73c), one estimate (97c)
Mar 28
8:32am ET
Molecular Templates Inc Raises Funds for Clinical Studies
Mar 28
8:16am ET
Molecular Templates announces $9.5M private placement
Mar 25
8:31am ET
Two new option listings and option delistings on March 25th
Mar 15
4:23pm ET
Molecular Templates Inc Faces BMS Collaboration Termination
Mar 04
8:19am ET
Molecular Templates provides interim update on its programs
No recent press releases are available for MTEM
MTEM Financials
Key terms
Ad Feedback
MTEM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MTEM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range